KIT and hepatocellular carcinoma: Overall, from the results of our in vitro kinase assays, phosphorylation expression, and in silico binding affinity, we confirmed that MBP-11901 targeted FLT3, VEGFR2, c-KIT, and PDGFRβ in HCC (Figure 7G).